A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia (REMDACTA)
COVID-19 Inpatient | COVID-19 Outpatient
What is the purpose of this trial?
This study will evaluate the efficacy and safety of combination therapy with remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized patients with COVID-19 pneumonia.
- Ages12 years and older
- Trial withGenentech, Inc.
- Start Date09/23/2020
- End Date07/30/2020
- Last Updated10/01/2020
- Study HIC#2000028556